Elite Pharmaceuticals, Inc. (ELTP)
0.2891
-0.01
(-2.00%)
USD |
OTCM |
Aug 24, 16:00
Elite Pharmaceuticals Net Income (Quarterly) : 5.911M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.911M |
| March 31, 2026 | 18.46M |
| December 31, 2025 | 18.59M |
| September 30, 2025 | 13.70M |
| June 30, 2025 | -5.885M |
| March 31, 2025 | 17.00M |
| December 31, 2024 | -10.89M |
| September 30, 2024 | -11.04M |
| June 30, 2024 | 0.6158M |
| March 31, 2024 | 3.326M |
| December 31, 2023 | 0.7064M |
| September 30, 2023 | 14.93M |
| June 30, 2023 | 1.142M |
| March 31, 2023 | -1.229M |
| December 31, 2022 | 2.970M |
| September 30, 2022 | 1.515M |
| June 30, 2022 | 0.3059M |
| March 31, 2022 | 2.429M |
| December 31, 2021 | 2.283M |
| September 30, 2021 | 1.797M |
| June 30, 2021 | 2.389M |
| March 31, 2021 | -0.4826M |
| December 31, 2020 | 2.012M |
| September 30, 2020 | 2.482M |
| June 30, 2020 | 1.077M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.9364M |
| December 31, 2019 | -1.861M |
| September 30, 2019 | -1.596M |
| June 30, 2019 | 0.2797M |
| March 31, 2019 | -2.664M |
| December 31, 2018 | -2.344M |
| September 30, 2018 | -2.584M |
| June 30, 2018 | -1.688M |
| March 31, 2018 | -2.829M |
| December 31, 2017 | -0.4902M |
| September 30, 2017 | 1.815M |
| June 30, 2017 | -2.169M |
| March 31, 2017 | -3.190M |
| December 31, 2016 | 1.667M |
| September 30, 2016 | 27.10M |
| June 30, 2016 | -1.049M |
| March 31, 2016 | 22.64M |
| December 31, 2015 | -37.02M |
| September 30, 2015 | -7.003M |
| June 30, 2015 | 11.16M |
| March 31, 2015 | -9.065M |
| December 31, 2014 | 21.02M |
| September 30, 2014 | 21.38M |
| June 30, 2014 | -4.402M |
| March 31, 2014 | -31.48M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Nektar Therapeutics | -40.62M |
| Daré Bioscience, Inc. | -2.983M |
| Eton Pharmaceuticals, Inc. | 11.58M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 32.36M |
| Total Expenses (Quarterly) | 26.44M |
| EPS Diluted (Quarterly) | 0.0052 |
| Enterprise Value | 278.03M |
| Gross Profit Margin (Quarterly) | 40.61% |
| Profit Margin (Quarterly) | 18.27% |
| Earnings Yield | 9.10% |
| Operating Earnings Yield | 11.03% |
| Normalized Earnings Yield | 2.802 |